Although the use of thiazolidinediones in the treatment of type 2 diabetes is controversial, they still comprise an important class of insulin-sensitizing drugs. In two reports, new evidence emerges that these drugs rely on the activation of their target, PPAR-γ, in the brain to improve hepatic insulin sensitivity and increase food intake and reduce energy expenditure.
- Min Lu
- David A Sarruf
- Jerrold M Olefsky
